Improved frost tolerance and winter survival in winter barley (Hordeum vulgare L.) by in vitro selection of proline overaccumulating lines

Euphytica ◽  
2004 ◽  
Vol 139 (1) ◽  
pp. 19-32 ◽  
Author(s):  
Hanny Tantau ◽  
Christiane Balko ◽  
B�rbel Brettschneider ◽  
Gilbert Melz ◽  
Karl D�rffling
Euphytica ◽  
1993 ◽  
Vol 67 (1-2) ◽  
pp. 151-154 ◽  
Author(s):  
A. M. R. Baillie ◽  
B. G. Rossnagel ◽  
K. K. Kartha

2011 ◽  
Vol 91 (6) ◽  
pp. 1105-1113 ◽  
Author(s):  
W. G. Legge ◽  
J. R. Tucker ◽  
B. Bizimungu ◽  
A. Tekauz ◽  
J. S. Noll ◽  
...  

Legge, W. G., Tucker, J. R., Bizimungu, B., Tekauz, A., Noll, J. S., Fetch Jr., T. G., Menzies, J. G., Haber, S., Savard, M. E., Vigier, B. J., Choo, T. M., Martin, R. A., Turkington, T. K., Rossnagel, B. G. and Harvey, B. L. 2011. Norman barley. Can. J. Plant Sci. 91: 1105–1113. Norman is a hulled two-row spring malting barley (Hordeum vulgare L.) cultivar derived from the cultivar CDC Kendall that was widely grown in western Canada and utilized commercially by the malting and brewing industry. Developed in 2000 by in vitro selection using deoxynivalenol mycotoxin in the medium of an anther culture system, Norman was evaluated in the Western Cooperative Two-row Barley Registration Test in 2005 and 2006, and the malting and brewing industry Collaborative Malting Barley Trials in 2006 and 2007, before being registered in 2009. Norman was also evaluated extensively for deoxynivalenol concentration in fusarium head blight (Fusarium graminearum Schwabe) nurseries from 2001 to 2009. Norman accumulates 25 to 30% less deoxynivalenol than its parent cultivar, CDC Kendall, but is similar in all other traits including malting quality.


2020 ◽  
Vol 65 (9-10) ◽  
pp. 3-7
Author(s):  
V. V. Gostev ◽  
Yu. V. Sopova ◽  
O. S. Kalinogorskaya ◽  
M. E. Velizhanina ◽  
I. V. Lazareva ◽  
...  

Glycopeptides are the basis of the treatment of infections caused by MRSA (Methicillin-Resistant Staphylococcus aureus). Previously, it was demonstrated that antibiotic tolerant phenotypes are formed during selection of resistance under the influence of high concentrations of antibiotics. The present study uses a similar in vitro selection model with vancomycin. Clinical isolates of MRSA belonging to genetic lines ST8 and ST239, as well as the MSSA (ATCC29213) strain, were included in the experiment. Test isolates were incubated for five hours in a medium with a high concentration of vancomycin (50 μg/ml). Test cultures were grown on the medium without antibiotic for 18 hours after each exposure. A total of ten exposure cycles were performed. Vancomycin was characterized by bacteriostatic action; the proportion of surviving cells after exposure was 70–100%. After selection, there was a slight increase in the MIC to vancomycin (MIC 2 μg/ml), teicoplanin (MIC 1.5–3 μg/ml) and daptomycin (MIC 0.25–2 μg/ml). According to the results of PAP analysis, all strains showed an increase in the area under curve depending on the concentration of vancomycin after selection, while a heteroresistant phenotype (with PAP/AUC 0.9) was detected in three isolates. All isolates showed walK mutations (T188S, D235N, E261V, V380I, and G223D). Exposure to short-term shock concentrations of vancomycin promotes the formation of heteroresistance in both MRSA and MSSA. Formation of VISA phenotypes is possible during therapy with vancomycin.


2002 ◽  
Vol 5 (6) ◽  
pp. 473-480
Author(s):  
Bentham Science Publisher A.N. Alexandrov ◽  
Bentham Science Publisher V.Yu. Alakhov ◽  
Bentham Science Publisher A.I. Miroshnikov

2000 ◽  
Vol 15 (4) ◽  
pp. 297-308 ◽  
Author(s):  
NAOZUMI TERAMOTO ◽  
YUKIO IMANISHI ◽  
YOSHIHIRO ITO

Sign in / Sign up

Export Citation Format

Share Document